205 related articles for article (PubMed ID: 25315362)
21. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
De Gioannis A; De Leo D
Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
[No Abstract] [Full Text] [Related]
22. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
[No Abstract] [Full Text] [Related]
23. Ketamine as treatment for depression.
Taiminen T
Duodecim; 2017; 133(1):52-60. PubMed ID: 29199810
[TBL] [Abstract][Full Text] [Related]
24. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
[TBL] [Abstract][Full Text] [Related]
25. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
Włodarczyk A; Cubała WJ
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
[TBL] [Abstract][Full Text] [Related]
26. Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.
Andrade C
Bipolar Disord; 2022 Mar; 24(2):113-114. PubMed ID: 34816542
[No Abstract] [Full Text] [Related]
27. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Zarate CA; Brutsche N; Laje G; Luckenbaugh DA; Venkata SL; Ramamoorthy A; Moaddel R; Wainer IW
Biol Psychiatry; 2012 Aug; 72(4):331-8. PubMed ID: 22516044
[TBL] [Abstract][Full Text] [Related]
28. [Ketamine for treatment of acute depression].
Hjerrild S; Bjerre J; Pedersen RH; Videbech P
Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
[TBL] [Abstract][Full Text] [Related]
29. Response to Zhang and Ho: Addressing Ketamine's Use in Depression.
Newport DJ; Nemeroff CB
Am J Psychiatry; 2016 Apr; 173(4):431-2. PubMed ID: 27035536
[No Abstract] [Full Text] [Related]
30. Can We Finally Dispense With Ketamine's Many Myths?
Hurwitz J
J Emerg Med; 2018 May; 54(5):697-700. PubMed ID: 29571922
[No Abstract] [Full Text] [Related]
31. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
[TBL] [Abstract][Full Text] [Related]
32. How much alcohol is in ketamine's antidepressant action?
Bonnet U
Life Sci; 2017 Jan; 168():54-57. PubMed ID: 27836553
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
34. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
Medicine (Baltimore); 2021 Jul; 100(29):e26769. PubMed ID: 34398056
[TBL] [Abstract][Full Text] [Related]
35. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
[TBL] [Abstract][Full Text] [Related]
36. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
Ford N; Ludbrook G; Galletly C
Aust N Z J Psychiatry; 2015 Dec; 49(12):1227. PubMed ID: 26058787
[No Abstract] [Full Text] [Related]
37. [Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review].
Romeo B; Choucha W; Fossati P; Rotge JY
Encephale; 2017 Aug; 43(4):354-362. PubMed ID: 27623117
[TBL] [Abstract][Full Text] [Related]
38. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
39. Ketamine for treatment-resistant depression: ready or not for clinical use?
Rush AJ
Am J Psychiatry; 2013 Oct; 170(10):1079-81. PubMed ID: 23982324
[No Abstract] [Full Text] [Related]
40. Ketamine's potential as a rapid antidepressant was overplayed.
Zhang MW; Ho RC
BMJ; 2015 Aug; 351():h4467. PubMed ID: 26290499
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
